NK042

BIOLOGICAL3 trials

Sponsors

Anhui Provincial Hospital, Shanghai NK Cell Technology Co., LTD, The Affiliated Hospital of Xuzhou Medical University

Conditions

Advanced Solid TumorsGynecologic CancerMultiple Sclerosis

Early Phase 1

An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).

Not yet recruitingNCT07546110

The Affiliated Hospital of Xuzhou Medical UniversityMultiple Sclerosis

Start: 2026-05-01End: 2028-12-30Target: 20Updated: 2026-04-22

Phase 1

A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites

Not yet recruitingNCT06415500

Anhui Provincial HospitalGynecologic Cancer

Start: 2024-05-06End: 2026-12-06Target: 9Updated: 2024-05-16

A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors

RecruitingNCT06773091

Shanghai NK Cell Technology Co., LTDAdvanced Solid Tumors

Start: 2025-02-07End: 2027-06-01Target: 76Updated: 2026-04-06